X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
index medicus (53) 53
aged (38) 38
female (35) 35
male (35) 35
middle aged (33) 33
treatment outcome (29) 29
peripheral vascular disease (27) 27
tissue plasminogen activator - therapeutic use (26) 26
clinical neurology (23) 23
stroke (23) 23
thrombolysis (23) 23
thrombolytic therapy (21) 21
stroke - drug therapy (18) 18
tissue plasminogen activator - adverse effects (17) 17
abridged index medicus (16) 16
acute ischemic-stroke (16) 16
fibrinolytic agents - therapeutic use (16) 16
double-blind method (15) 15
time factors (14) 14
tissue plasminogen activator - administration & dosage (14) 14
aged, 80 and over (13) 13
alteplase (13) 13
clinical trials (13) 13
double-blind (13) 13
tissue plasminogen activator (13) 13
tissue-plasminogen activator (13) 13
fibrinolytic agents - adverse effects (12) 12
risk factors (12) 12
medicine, general & internal (11) 11
mortality (11) 11
randomized controlled trials as topic (11) 11
adult (10) 10
age factors (10) 10
drug therapy (10) 10
ecass (10) 10
therapy (10) 10
thrombolytic therapy - methods (10) 10
heart attack (9) 9
odds ratio (9) 9
acute disease (8) 8
brain ischemia - drug therapy (8) 8
care and treatment (8) 8
fibrinolytic agents - administration & dosage (8) 8
intravenous thrombolysis (8) 8
outcomes (8) 8
analysis (7) 7
atlantis (7) 7
cardiac & cardiovascular systems (7) 7
cerebrovascular disorders - drug therapy (7) 7
heart attacks (7) 7
human necessities (7) 7
hygiene (7) 7
medical or veterinary science (7) 7
patient outcomes (7) 7
preparations for medical, dental, or toilet purposes (7) 7
stroke - epidemiology (7) 7
blood pressure (6) 6
brain ischemia - complications (6) 6
cardiac patients (6) 6
controlled-trial (6) 6
infusions, intravenous (6) 6
logistic models (6) 6
medical imaging (6) 6
prognosis (6) 6
randomized controlled trials as topic - statistics & numerical data (6) 6
risk (6) 6
safety (6) 6
severity of illness index (6) 6
stroke - diagnosis (6) 6
survival analysis (6) 6
acute stroke (5) 5
calculating (5) 5
computing (5) 5
counting (5) 5
data interpretation, statistical (5) 5
data processing systems or methods, specially adapted foradministrative, commercial, financial, managerial, supervisoryor forecasting purposes (5) 5
electrocardiography (5) 5
endocrinology & metabolism (5) 5
follow-up studies (5) 5
health aspects (5) 5
hemorrhage (5) 5
myocardial infarction - drug therapy (5) 5
physics (5) 5
randomized-trial (5) 5
research design (5) 5
retrospective studies (5) 5
rt-pa (5) 5
systems or methods specially adapted for administrative,commercial, financial, managerial, supervisory or forecastingpurposes, not otherwise provided for (5) 5
thrombolytic therapy - adverse effects (5) 5
tissue-plasminogen-activator (5) 5
tomography, x-ray computed (5) 5
united states (5) 5
acute ischemic stroke (4) 4
article (4) 4
brain ischemia - diagnosis (4) 4
cardiovascular disease (4) 4
cerebral hemorrhage - chemically induced (4) 4
cerebral hemorrhage - epidemiology (4) 4
cerebrovascular disorders - diagnostic imaging (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9727, pp. 1695 - 1703
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 15, pp. 1402 - 1411
In a randomized trial, 1006 patients with intermediate-risk pulmonary embolism were assigned to tenecteplase or placebo in addition to standard heparin... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | VENOUS THROMBOEMBOLISM | ELEVATION | COMPLICATIONS | ECHOCARDIOGRAPHY | THROMBOLYTIC THERAPY | RIGHT-VENTRICULAR ENLARGEMENT | PROGNOSTIC ROLE | Pulmonary Embolism - complications | Age Factors | Double-Blind Method | Humans | Middle Aged | Risk Factors | Heparin - therapeutic use | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Pulmonary Embolism - mortality | Fibrinolytic Agents - adverse effects | Stroke - chemically induced | Fibrinolytic Agents - therapeutic use | Ventricular Dysfunction, Right - etiology | Aged, 80 and over | Troponin - blood | Female | Pulmonary Embolism - drug therapy | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Pulmonary embolism | Evaluation | Usage | Care and treatment | Fibrinolysis | Heart | Stroke | Heart attacks | Echocardiography | Embolisms | Pulmonary arteries | Lung | Hemorrhage | Bleeding | Embolism | Blood clots | Troponin T | Fibrin | Troponin | Troponin I | Motivation | Computed tomography | Ischemia | Calcium-binding protein | Heparin | Ventricle | Drug therapy | Index Medicus | Abridged Index Medicus | Ventricular Dysfunction, Right | Fibrinolytic Agents | Life Sciences | Tissue Plasminogen Activator | Pulmonary Embolism
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 9, pp. 925 - 933
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 22, pp. 2117 - 2128
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 15, pp. 1379 - 1387
Reperfusion strategies with fibrinolysis or primary PCI were compared in this trial involving patients with ST-segment elevation myocardial infarction (STEMI).... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | RANDOMIZED-TRIAL | DELAYS | REPERFUSION STRATEGY | Recurrence | Myocardial Infarction - mortality | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Tissue Plasminogen Activator - therapeutic use | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Angioplasty, Balloon, Coronary | Heart Failure - prevention & control | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy - methods | Ticlopidine - adverse effects | Electrocardiography | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Time-to-Treatment | Intracranial Hemorrhages - etiology | Kaplan-Meier Estimate | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Aged | Drugs | Dose-response relationship (Biochemistry) | Usage | Care and treatment | Angiography | Angioplasty | Patient outcomes | Product/Service Evaluations | Thrombolytic drugs | Heart attack | Dosage and administration | Diagnosis | Drug therapy | Myocardial infarction | Anticoagulants | Fibrin | Heart attacks | Medical imaging | Reperfusion | Clopidogrel | Congestive heart failure | Fibrinolysis | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article